Drugs / 18F-MK-6240
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03757910 | Oct 2019 → Jan 2023 | Alzheimer disease | José A. Luchsinger | Terminated | No outcome recorded Stop: Enrollment |
| Phase 12 trials | ||||||
| Phase 1 | NCT03706261 | Mar 2019 → Jul 2023 | Alzheimer disease | Adam Brickman | Completed | No outcome recorded |
| Phase 1 | NCT02562989 | Oct 2015 → Dec 2016 | Alzheimer disease, amnestic disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04576793 | Nov 2020 → May 2027 expected | Alzheimer disease | Columbia University | Recruiting | No outcome recorded |
| Phase 2 | NCT03389100 | Jul 2018 → Jun 2026 overdue | prediabetes syndrome, type 2 diabetes mellitus | Columbia University | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT03373604 | Dec 2017 → May 2022 | Alzheimer disease | Patrick Lao | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06860373 | Jun 2023 → Apr 2024 | Down syndrome | LuMind IDSC Foundation | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06999434 Background | May 2025 → May 2030 expected | Alzheimer disease, multiple sclerosis, radiculopathy, spinal cord injury | Yale University | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-11-05 | Sinotau Pharmaceutical Group | Regulatory DA受理先通医药合作伙伴Lantheus创新核药上市申请 sinotau.com ↗
先通医药合作伙伴Lantheus(NASDAQ: LNTH)近日宣布，其在研产品 MK-6240（亦称为XTR006）的新药上市申请（NDA）已获得美国食品药品监督管理局（FDA）正式受理。 |
| 2025-10-28 | Lantheus Medical Imaging | Regulatory Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease lantheus.com ↗ |
| 2025-04-30 | Lantheus Medical Imaging | Results Lantheus Announces Alzheimer’s Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies lantheus.com ↗
This achievement reinforces the potential of MK-6240 as a valuable diagnostic tool. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-05 | Sinotau Pharmaceutical Group | DA受理先通医药合作伙伴Lantheus创新核药上市申请 sinotau.com ↗ |
| 2025-10-28 | Lantheus Medical Imaging | Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease lantheus.com ↗ |
| 2025-04-30 | Lantheus Medical Imaging | Lantheus Announces Alzheimer’s Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies lantheus.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-MK-6240 | “18F-MK-6240 (18F-labeled 6-(fluoro)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine) is a highly selective, subnanomolar-affinity PET tracer for imaging neurofibrillary...” PMID 29880509 ↗ Jun 2018 |
| Modality | Diagnostic / imaging agent | “a Positron Emission Tomography (PET) imaging agent” NCT02562989 ↗ |
| Route | Intravenous | “single intravenous (IV) dose” NCT02562989 ↗ |